CL2015002723A1 - Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23 - Google Patents

Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23

Info

Publication number
CL2015002723A1
CL2015002723A1 CL2015002723A CL2015002723A CL2015002723A1 CL 2015002723 A1 CL2015002723 A1 CL 2015002723A1 CL 2015002723 A CL2015002723 A CL 2015002723A CL 2015002723 A CL2015002723 A CL 2015002723A CL 2015002723 A1 CL2015002723 A1 CL 2015002723A1
Authority
CL
Chile
Prior art keywords
antibody
methods
treat psoriasis
psoriasis
treat
Prior art date
Application number
CL2015002723A
Other languages
English (en)
Spanish (es)
Inventor
Wayne Tsuji
John P Gibbs
Wei-Jian Pan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50336511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002723(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2015002723A1 publication Critical patent/CL2015002723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
CL2015002723A 2013-03-15 2015-09-15 Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23 CL2015002723A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361789777P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002723A1 true CL2015002723A1 (es) 2016-03-28

Family

ID=50336511

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002723A CL2015002723A1 (es) 2013-03-15 2015-09-15 Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23

Country Status (17)

Country Link
US (3) US20160060337A1 (https=)
EP (2) EP3689369A1 (https=)
JP (4) JP2016517408A (https=)
KR (1) KR20150128858A (https=)
CN (1) CN105209064A (https=)
AP (1) AP2015008803A0 (https=)
AU (3) AU2014238148A1 (https=)
CA (1) CA2906382A1 (https=)
CL (1) CL2015002723A1 (https=)
CR (1) CR20150572A (https=)
EA (1) EA201591581A1 (https=)
HK (1) HK1219425A1 (https=)
IL (2) IL241342A0 (https=)
PH (2) PH12015502129A1 (https=)
SG (2) SG11201507482UA (https=)
TN (1) TN2015000403A1 (https=)
WO (1) WO2014149425A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
AU2016215535B2 (en) * 2015-02-04 2021-09-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
CN109071653A (zh) * 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
JP6728392B2 (ja) * 2016-04-15 2020-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法
US20200025776A1 (en) * 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
CA3118964A1 (en) * 2018-11-05 2020-05-14 Merck Sharp & Dohme Corp. Dosing regimen of anti-tigit antibody for treatment of cancer
JP2022526493A (ja) * 2019-03-18 2022-05-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
CN101389769A (zh) * 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009117289A2 (en) * 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
EP2301119B1 (en) 2008-06-30 2015-05-13 Black & Decker, Inc. Cord protector for power tools
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
CN103813804A (zh) * 2010-10-06 2014-05-21 Abbvie公司 用于治疗银屑病的方法
CN103154031A (zh) * 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.

Also Published As

Publication number Publication date
HK1219425A1 (zh) 2017-04-07
PH12019502700A1 (en) 2020-12-07
CN105209064A (zh) 2015-12-30
AU2014238148A1 (en) 2015-10-08
IL241342A0 (en) 2015-11-30
AP2015008803A0 (en) 2015-10-31
CA2906382A1 (en) 2014-09-25
SG11201507482UA (en) 2015-10-29
EP2968488A1 (en) 2016-01-20
AU2019200206A1 (en) 2019-01-31
JP2023011815A (ja) 2023-01-24
JP2016517408A (ja) 2016-06-16
US20160060337A1 (en) 2016-03-03
CR20150572A (es) 2016-04-25
SG10201804954UA (en) 2018-07-30
US20200277368A1 (en) 2020-09-03
TN2015000403A1 (en) 2017-01-03
JP2021102644A (ja) 2021-07-15
EA201591581A1 (ru) 2016-01-29
AU2020270495A1 (en) 2020-12-17
US20220135668A1 (en) 2022-05-05
JP2020063237A (ja) 2020-04-23
KR20150128858A (ko) 2015-11-18
EP3689369A1 (en) 2020-08-05
PH12015502129A1 (en) 2016-01-25
IL275093A (en) 2020-07-30
WO2014149425A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
CL2015002723A1 (es) Métodos para tratar la psoriasis utilizando un anticuerpo anti-il-23
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
BR112015030351A2 (pt) método e aparelho para realização de transações locais
BR112015020236A2 (pt) método e aparelho para comunicação focalizada de dados
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
CL2015001929A1 (es) Sistema y método optico para seleccionar semillas
CL2017002728A1 (es) Método para el tratamiento de cáncer
CL2015003049A1 (es) Variantes de pertuzumab y su evaluación
AR091700A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
ES2813450T8 (es) Compuestos y métodos para tratar un trastorno epiléptico
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
EP3022216C0 (en) IMPROVED PROCESS FOR ORGANIC SOLVENT TREATMENT OF LIGNOCELLULOSIC BIOMASS
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112013031968A2 (pt) método e aparelho para testes magnéticos
BR112016014327A2 (pt) método e aparelho para predição de tabela de paleta
BR112013028187A2 (pt) processo para produzir olefinas
BR112014000351A2 (pt) “método para tratamento prévio de biomassa lignocelulósica”
IL266607A (en) A method for treating eczema with a specific anti-IL-23 antibody
BR112013029484A2 (pt) método para o tratamento de tumores sólidos avançados
EA201690990A1 (ru) Способы получения ингибиторов фосфатидилинозитол-3-киназы
BR112013024363A2 (pt) método, e aparelho
UY34708A (es) Metodo para producir glicósidos de esteviol
BR112013032218A2 (pt) método para coprodução de hidrocarbonetos
BR112013023227A2 (pt) método para tratar perda de circulação, e material de circulação perdida de gelificação (lcm)
BR112015023511A2 (pt) tensor